NVCR250117P45000
- 24.75
- 0.000.00%
Novocure Newsroom
Express News | Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025
Piper Sandler Maintains Overweight on NovoCure, Raises Price Target to $42
NovoCure Analyst Ratings
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Why NovoCure Stock Was Winning Big This Week
Express News | Novocure Ltd : JP Morgan Raises Target Price to $29 From $19
A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $30 to $40
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
Novocure Is Maintained at Buy by HC Wainwright & Co.
Zai Lab, Novocure Announce PANOVA-3 Trial Met Primary Endpoint
Novocure Shares Jump Nearly 50% on Trial Results for Pancreatic Cancer Therapy
U.S. Small Caps Close Mixed As Novocure Lead, Archer Aviation Lags
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Update: NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint
HC Wainwright & Co. Reiterates Buy on NovoCure, Raises Price Target to $38
Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating